Atara Biotherapeutics IncNASDAQ:ATRA
- LAST PRICE12.1300
- TODAY'S CHANGE (%)0.6600 (5.7541%)
- Bid / Lots11.6000/ 1
- Ask / Lots12.5000/ 6
- Open / Previous Close11.5700 / 11.4700
- Day Range
- 52 Week Range
- Volume87,726
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATRA |
|---|---|---|
| 09:32 ET | 1305 | 11.57 |
| 09:42 ET | 1000 | 11.68 |
| 09:44 ET | 1100 | 11.82 |
| 09:48 ET | 1149 | 11.75 |
| 09:50 ET | 1254 | 11.855 |
| 09:51 ET | 5852 | 11.8562 |
| 09:53 ET | 2508 | 11.9599 |
| 09:55 ET | 233 | 11.96 |
| 10:00 ET | 100 | 11.75 |
| 10:02 ET | 609 | 11.7971 |
| 10:04 ET | 200 | 11.845 |
| 10:08 ET | 197 | 11.9091 |
| 10:09 ET | 3700 | 12.055 |
| 10:11 ET | 800 | 12.105 |
| 10:13 ET | 882 | 12.0435 |
| 10:15 ET | 4828 | 12.1303 |
| 10:18 ET | 132 | 12.165 |
| 10:20 ET | 1297 | 12.04 |
| 10:22 ET | 200 | 12.16 |
| 10:24 ET | 1108 | 12.0714 |
| 10:26 ET | 2000 | 12.0001 |
| 10:27 ET | 150 | 12 |
| 10:33 ET | 325 | 11.957 |
| 10:36 ET | 912 | 11.9955 |
| 10:45 ET | 385 | 12.156 |
| 10:49 ET | 299 | 12.17 |
| 10:51 ET | 2600 | 12.205 |
| 10:54 ET | 1794 | 12.28 |
| 11:00 ET | 500 | 12.25 |
| 11:02 ET | 200 | 12.13 |
| 11:03 ET | 100 | 12.065 |
| 11:05 ET | 100 | 12.065 |
| 11:16 ET | 500 | 12.055 |
| 11:18 ET | 100 | 12.055 |
| 11:23 ET | 500 | 12.061 |
| 11:30 ET | 500 | 12.055 |
| 11:32 ET | 600 | 12.05 |
| 11:38 ET | 400 | 11.85 |
| 11:59 ET | 100 | 11.94 |
| 12:08 ET | 100 | 11.9 |
| 12:10 ET | 100 | 11.76 |
| 12:32 ET | 150 | 11.7239 |
| 12:35 ET | 800 | 11.73 |
| 12:39 ET | 212 | 11.8889 |
| 01:06 ET | 3204 | 12.015 |
| 01:08 ET | 408 | 11.94 |
| 01:15 ET | 100 | 11.885 |
| 01:18 ET | 2150 | 11.965 |
| 01:24 ET | 1200 | 11.86 |
| 01:31 ET | 100 | 11.95 |
| 01:40 ET | 186 | 11.8369 |
| 01:45 ET | 100 | 12.01 |
| 01:49 ET | 100 | 12.005 |
| 02:02 ET | 100 | 12 |
| 02:05 ET | 1000 | 12 |
| 02:12 ET | 500 | 12.15 |
| 02:14 ET | 393 | 12.19 |
| 02:18 ET | 1000 | 12.145 |
| 02:20 ET | 1000 | 12.15 |
| 02:21 ET | 100 | 12.1539 |
| 02:23 ET | 1600 | 12.115 |
| 02:27 ET | 1000 | 12.155 |
| 02:32 ET | 100 | 12.11 |
| 02:36 ET | 2505 | 12.19 |
| 02:38 ET | 300 | 12.1 |
| 02:43 ET | 3382 | 12.25 |
| 02:48 ET | 560 | 12.315 |
| 02:57 ET | 100 | 12.245 |
| 03:08 ET | 700 | 12.095 |
| 03:10 ET | 700 | 12.22 |
| 03:24 ET | 100 | 12.29 |
| 03:28 ET | 500 | 12.23 |
| 03:32 ET | 600 | 12.16 |
| 03:46 ET | 1600 | 12.225 |
| 03:50 ET | 100 | 12.17 |
| 03:55 ET | 200 | 12.195 |
| 03:57 ET | 100 | 12.195 |
| 04:00 ET | 600 | 12.13 |
Nov 13, 2024
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Atara Biotherapeutics 3Q Loss/Shr $2.93 >ATRA, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow JonesSidoti Events, LLC's Virtual November Micro-Cap Conference, from 8:32AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:32AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
Press Release: Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024, from 4:03PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:03PM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Atara Biotherapeutics Inc | 65.0M | -0.5x | --- |
Clearside Biomedical Inc | 81.9M | -2.4x | --- |
Cue Biopharma Inc | 61.4M | -1.2x | --- |
CervoMed Inc | 79.2M | -5.5x | --- |
Kronos Bio Inc | 54.4M | -0.6x | --- |
Affimed NV | 39.9M | -0.6x | --- |
Company Information
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Contact Information
- Headquarters
- 2380 Conejo Spectrum St, Suite 200THOUSAND OAKS, CA, United States 91320
- Phone
- 805-623-4244
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Pascal Touchon
- President, Chief Executive Officer, Director
- Anhco Nguyen
- Chief Financial Officer, Executive Vice President
- Eric Hyllengren
- Executive Vice President - Global Head Regulatory Affairs and Quality
- Jill Henrich
- Lead Independent Director
- Carol Gallagher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $65.0M |
|---|---|
Revenue (TTM) | $100.4M |
Shares Outstanding | 5.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-26.44 |
Book Value | $-23.31 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -130.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
